DK1267909T3 - Fremgangsmåder til blokering af vævsdestruktion ved autoreaktive T-celler - Google Patents

Fremgangsmåder til blokering af vævsdestruktion ved autoreaktive T-celler

Info

Publication number
DK1267909T3
DK1267909T3 DK01933358.2T DK01933358T DK1267909T3 DK 1267909 T3 DK1267909 T3 DK 1267909T3 DK 01933358 T DK01933358 T DK 01933358T DK 1267909 T3 DK1267909 T3 DK 1267909T3
Authority
DK
Denmark
Prior art keywords
cells
methods
autoreactive
polypeptide
purified
Prior art date
Application number
DK01933358.2T
Other languages
English (en)
Inventor
Yang Liu
Pan Zheng
Xue-Feng Bai
Original Assignee
Univ Ohio State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ohio State Res Found filed Critical Univ Ohio State Res Found
Application granted granted Critical
Publication of DK1267909T3 publication Critical patent/DK1267909T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
DK01933358.2T 2000-03-29 2001-03-29 Fremgangsmåder til blokering af vævsdestruktion ved autoreaktive T-celler DK1267909T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19281400P 2000-03-29 2000-03-29
PCT/US2001/040390 WO2001072325A1 (en) 2000-03-29 2001-03-29 Methods of blocking tissue destruction by autoreactive t cells

Publications (1)

Publication Number Publication Date
DK1267909T3 true DK1267909T3 (da) 2010-11-08

Family

ID=22711138

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01933358.2T DK1267909T3 (da) 2000-03-29 2001-03-29 Fremgangsmåder til blokering af vævsdestruktion ved autoreaktive T-celler

Country Status (8)

Country Link
EP (1) EP1267909B1 (da)
JP (1) JP2004500110A (da)
AT (1) ATE475428T1 (da)
AU (2) AU5979201A (da)
CA (1) CA2404340C (da)
DE (1) DE60142684D1 (da)
DK (1) DK1267909T3 (da)
WO (1) WO2001072325A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030106084A1 (en) 2000-03-29 2003-06-05 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
NZ603196A (en) * 2010-04-28 2014-07-25 Oncolmmune Inc Methods of use of soluble cd24 for therapy of rheumatoid arthritis
WO2014011987A1 (en) * 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating car t cells
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
MY181834A (en) 2014-07-21 2021-01-08 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
JP6736540B2 (ja) 2014-07-21 2020-08-05 ノバルティス アーゲー Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置
CN107207597A (zh) * 2014-11-06 2017-09-26 儿研所儿童医学中心 用于癌症和自身免疫疾病的免疫疗法
AU2016258084B2 (en) * 2015-05-07 2020-01-30 Oncoimmune, Inc. Use of CD24 for lowering low-density lipoprotein cholesterol levels
US10639350B2 (en) 2015-08-10 2020-05-05 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods and pharmaceutical compositions for improving wound healing using CD24
CA3012466A1 (en) * 2016-02-02 2017-08-10 Oncoimmune, Inc. Use of cd24 proteins for treating leptin-deficient conditions
SG11201908077XA (en) * 2017-03-07 2019-09-27 Oncoimmune Inc Methods of use of soluble cd24 for treating systemic lupus erythematosus
US20200181235A1 (en) * 2017-05-15 2020-06-11 Oncoimmune, Inc. Methods of use of soluble cd24 for neuroprotection and remyelination
AU2019284911B2 (en) 2018-06-13 2026-04-09 Novartis Ag BCMA chimeric antigen receptors and uses thereof

Also Published As

Publication number Publication date
ATE475428T1 (de) 2010-08-15
EP1267909A1 (en) 2003-01-02
JP2004500110A (ja) 2004-01-08
WO2001072325A9 (en) 2003-02-20
CA2404340C (en) 2012-10-16
EP1267909A4 (en) 2006-05-03
DE60142684D1 (de) 2010-09-09
CA2404340A1 (en) 2001-10-04
AU2001259792B2 (en) 2005-12-22
WO2001072325A1 (en) 2001-10-04
AU5979201A (en) 2001-10-08
EP1267909B1 (en) 2010-07-28

Similar Documents

Publication Publication Date Title
Brentjens et al. Interstitial immune complex nephritis in patients with systemic lupus erythematosus
KR100426113B1 (ko) 티(t)-세포항원,및티(t)-세포매개증상의진단및치료에있어서의이의용도
Hart et al. Endogenously produced Ia antigens within cells of convoluted tubules of rat kidney.
AU5979201A (en) Methods of blocking tissue destruction by autoreactive t cells
EP0837696A4 (en) IMPROVED DELIVERY OF DIAGNOSTIC AND THERAPEUTIC SUBSTANCES AT ONE DESTINATION
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
ES2180754T3 (es) Compuestos y metodos para la deteccion de infeccion por t. cruzi.
EP0751992A4 (en) VASCULAR ENDOTHELIAL GROWTH FACTOR 2
KR927003816A (ko) Cd3에 대한 항체
ES2293973T3 (es) Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos.
ATE506076T1 (de) Medizinische verwendung von anti-cs1 antikörpern
NO331072B1 (no) Sammensetning som omfatter et angiogenese inhiberende middel og et anti tumor-immunoterapeutisk middel samt anvendelser av det samme.
TR200200781T1 (tr) Birlikte uyaran bir sinyal transdüksiyon molekülü olan ailime karşı insan monoklonal antikoru ve bunun farmasötik kullanımı
Hansen et al. A mouse aminopeptidase N is a marker for antigen‐presenting cells and appears to be co‐expressed with major histocompatibility complex class II molecules
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
MX9705610A (es) Anticuerpos monoclonales especificos para diferentes epitopos de la gp39 humana y metodos para su uso en diagnostico y terapia.
UA40611C2 (uk) Імунокон'югат, спосіб його виготовлення, фармацевтична композиція
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
PT1132097E (pt) Ancoras celulares e de proteinas sericas e conjugados
DE68925226D1 (de) Monoklonale Antikörper
Trune et al. Failure of elevated heat shock protein 70 antibodies to alter cochlear function in mice
ATE442439T1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
RU94045907A (ru) Вич-антитела человека или их фрагменты, экспрессионные кассеты, клетки-хозяева, фармацевтические композиции, способ защиты
ATE235551T1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
US20090130021A1 (en) Methods, products and uses involving platelets and/or the vasculature